Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Gorski

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 4, 2009
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycinSara K Quinney, Xin Zhang, Aroonrut Lucksiri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2005
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearanceSilvana Borges, Lang Li, Mitchell A Hamman, et al.
British Journal of Clinical Pharmacology|July 20, 2007
Interaction between midazolam and clarithromycin in the elderlySara K Quinney, Barbara D Haehner, Melissa B Rhoades, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2006
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazoleJenny Y Chien, Aroonrut Lucksiri, Charles S Ernest, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substratesGirum L Lemma, Zaiqi Wang, Mitchell A Hamman, et al.
Journal of the American Society of Nephrology : JASN|April 24, 2001
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patientsNaga Chalasani, J Christopher Gorski, John C Horlander, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2003
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activityBryan A Ward, J Christopher Gorski, David R Jones, et al.
Journal of Clinical Pharmacology|September 3, 2004
Intramuscular haloperidol or lorazepam and QT intervals in schizophreniaAnne T Harvey, David Flockhart, J Christopher Gorski, et al.
Hepatology (Baltimore, Md.)|February 26, 2003
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitisNaga Chalasani, J Christopher Gorski, Maleeha S Asghar, et al.
Journal of Clinical Gastroenterology|October 22, 2010
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shuntRaj Vuppalanchi, Ravi Juluri, Marwan Ghabril, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 4, 2009
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycinSara K Quinney, Xin Zhang, Aroonrut Lucksiri, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2005
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearanceSilvana Borges, Lang Li, Mitchell A Hamman, et al.
British Journal of Clinical Pharmacology|July 20, 2007
Interaction between midazolam and clarithromycin in the elderlySara K Quinney, Barbara D Haehner, Melissa B Rhoades, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 14, 2006
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazoleJenny Y Chien, Aroonrut Lucksiri, Charles S Ernest, et al.
Clinical Pharmacology and Therapeutics|March 4, 2006
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substratesGirum L Lemma, Zaiqi Wang, Mitchell A Hamman, et al.
Journal of the American Society of Nephrology : JASN|April 24, 2001
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patientsNaga Chalasani, J Christopher Gorski, John C Horlander, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2003
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activityBryan A Ward, J Christopher Gorski, David R Jones, et al.
Journal of Clinical Pharmacology|September 3, 2004
Intramuscular haloperidol or lorazepam and QT intervals in schizophreniaAnne T Harvey, David Flockhart, J Christopher Gorski, et al.
Hepatology (Baltimore, Md.)|February 26, 2003
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitisNaga Chalasani, J Christopher Gorski, Maleeha S Asghar, et al.
Journal of Clinical Gastroenterology|October 22, 2010
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shuntRaj Vuppalanchi, Ravi Juluri, Marwan Ghabril, et al.
Pageof 4